OUR TEAM

One vision, one mission, one team

Our Leadership

Zhou Lihan

Executive Director, Co-founder & Chief Executive Officer

Zou Ruiyang

Executive Director, Co-founder & Chief Technology Officer

Isaac Ho

Executive Director & Chief Investment Officer

Choo Beng Lor

Chief Financial Officer

Martin Law

Chief Investor Relations Officer & Managing Director, Hong Kong

Vitoria Owyong

General Counsel & Company Secretary

Our Advisors

Our scientific advisory board (SAB) provides external scientific review of our research and development activities and strategy.

The MiRXES SAB is chaired by MiRXES Co-founder and Chief Scientific Advisor Professor Too Heng-Phon.

Prof. Too Heng-Phon

PhD

Associate Professor of Biochemistry, National University of Singapore

Associate Professor of Chemical and Biomolecular Engineering, National University of Singapore

Co-founder & Chief Scientific Advisor, MiRXES

Prof. Frank Slack

PhD

Shields Warren Mallinckrodt Professor of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center

Director, Harvard Medical School Initiative for RNA Medicine at Beth Israel Deaconess Medical Center

Co-discoverer of the second known microRNA and the first human microRNA

Prof. Chng Wee Joo

MB ChB, PhD, MRCP, DipRCPath, MRCPath

Director, National University Cancer Institute, National University Health System

Group Director of Research, National University Health System

Deputy Director & Senior Principal Investigator, Cancer Science Institute, Singapore

Vice Dean of Research & Provost’s Chair Professor, Yong Loo Lin School of Medicine, National University of Singapore

Chief Medical Advisor, MiRXES

Prof. Lam Kong Peng

PhD

Professor of Microbiology and Immunology, National University of Singapore

Executive Director, Singapore Immunology Network, A*STAR

Prof. Takahiro Ochiya

PhD

Professor of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University

Chief Scientific Officer, Theoria Science

President, Japanese Society for Extracellular Vesicles

Prof. Yeoh Khay Guan

MBBS, MMed, FRCP (London), FRCP (Glasg), FAMS

Irene Tan Liang Kheng Professor in Medicine and Oncology, National University of Singapore

Senior Consultant, Gastroenterology and Hepatology, National University Hospital

Lead Principal Investigator, Singapore Gastric Cancer Consortium

Chairman, National Colorectal Cancer Screening Committee, Health Promotion Board, Ministry of Health, Singapore

Chief Executive, National University Health System

Senior Vice President (Health Affairs), National University of Singapore

Dr. Holger Heyn

PhD

Leader, Single Cell Genomics Team, Spanish National Centre for Genomic Analysis (CNAG-CRG), Barcelona, Spain

Scientific Co-founder, Omniscope

Prof. Tony Mok

BMSc, MD, FRCP(C), FRCP(Edin), FRCP(Lond), FHKCP, FHKAM(Medicine), FASCO, Member of ASHK

Chairman of the Department of Clinical Oncology, The Chinese University of Hong Kong

Li Shu Fan Professor of Clinical Oncology, The Chinese University of Hong Kong

Past President, International Association for the Study of Lung Cancer (IASLC)

SOCIAL MEDIA

Linkedin-in Facebook-f Instagram

ABOUT

SOLUTIONS

TECHNOLOGY

PIPELINE

INVESTOR RELATIONS

NEWSROOM

Copyright © 2022 MiRXES Pte Ltd. All rights reserved. | Privacy Policy
Scroll to Top

Zhou Lihan

Ph.D.

Executive Director, Co-founder & Chief Executive Officer

Zhou Lihan is the Executive Director, Co-founder and Chief Executive Officer of MiRXES. Lihan led MiRXES’ growth from a 3-man start-up in Singapore to a leader in RNA technology and disease early detection with operations globally.

Prior to founding MiRXES, Lihan led a research team at the Bioprocessing Technology Institute, A*STAR to develop a novel microRNA qPCR assay platform for biomarker and therapeutic target discovery. In 2015, Lihan was recognized by the MIT Technology Review as a member of the Innovators Under 35.

Lihan obtained his Ph.D. in Biochemistry from Yong Loo Lin School of Medicine, National University of Singapore. Lihan has authored and co-authored more than 20 peer-reviewed publications and several patent applications.

Zou Ruiyang

Ph.D.

Executive Director, Co-founder & Chief Technology Officer

Zou Ruiyang is Executive Director, Co-founder and Chief Technology Officer of MiRXES. Ruiyang is responsible for MiRXES’s technology and diagnostic test development, and also oversees MiRXES’s China operations.

Prior to founding MiRXES, he was the Head of Bioinformatics at the MicroRNA Signature Identification Center, A*STAR. Ruiyang has a passion for science and is continuously innovating to discover technology that can be developed to practical applications that can be delivered to the public.

Ruiyang has a PhD in Chemical and Pharmaceutical Engineering from Singapore-MIT Alliance (NUS-MIT), Singapore. He also successfully completed his dual degree in 2007 where he attained Bachelor of Science, Molecular Science and Engineering, Nankai University, Tianjin, P. R. China, and Bachelor of Engineering, Molecular Science and Engineering, Tianjin University, Tianjin, P. R. China. Ruiyang has co-authored more than 10 publications and has eight patents and applications.

Isaac Ho

Executive Director and Chief Investment Officer

Isaac Ho is Executive Director and Chief Investment Officer of MiRXES where he oversees corporate development, investor relations as well as builds strategic partnerships with key healthcare players and financial institutions.

Prior to MiRXES, Isaac founded Singapore Health, and subsequently VentureCraft Group, a Singapore government accredited co-investment partner and incubator in the healthcare and biomedical sciences sector. He is a veteran in entrepreneurship, investment, and business management. Under his leadership, Venturecraft Group was appointed as an accelerator under SPRING Singapore’s Sector Specific Accelerator Program for Biomedical Sciences.

Isaac graduated from Deakin University with a Bachelor’s Degree in Commerce (Marketing and Management).

Choo Beng Lor

Chief Financial Officer

Choo Beng Lor is the Chief Financial Officer of MiRXES and is responsible for matters relating to finance, internal controls, compliance, corporate management and investor relations.

He was previously with Zheneng Jinjiang Environment Holding Company Limited where he was the Financial Controller overseeing matters relating to financial management and reporting, compliance with post-listing obligations. Prior to that, Beng Lor spent 11 years being a CFO for companies including Cima NanoTech Pte Ltd, Sound Global Ltd and Sino Chemical Holdings Pte Ltd.

Beng Lor graduated with a Bachelor of Accountancy from Nanyang Technological University, Singapore. He is a Chartered Accountant of the Institute of Singapore Chartered Accountants.

Martin Law

Chief Investor Relations Officer & Managing Director, Hong Kong

Martin Law is the Chief Investor Relations Officer of the MiRXES Group where he oversees investor relations, strategic communication, corporate development and M&As of the group, he also works closely with CIO & CFO on finance, investment and treasury matters.

Martin is also the Managing Director of MiRXES Hong Kong. He leads the business development, manages operations and upholds governance of MiRXES’ businesses in Hong Kong and Greater Bay Area.

Martin is a qualified accountant with over 30 years of experience in finance management, investor relations, corporate development, investment and corporate finance, in industries such as banking, insurance, and medical & healthcare. Martin was previously the Chief Financial Officer of a number of multinational corporations, including Lloyd’s of London China, ANZ Bank China, and a Hong Kong listed medical & healthcare group. Martin is currently the Independent Non-Executive Director (INED) of a dual-listed company, Liaoning Port Co. Ltd. (2180.HK/601880.SH)

Martin holds an MBA degree and is a Chartered Management Accountant (ACMA), Chartered Global Management Accountant (CGMA), Certified Information Systems Auditor (CISA), as well as an Associate of the Chartered Institute of Arbitrator (ACIArb). Martin is also a Fellow of the Hong Kong Institute of Directors (FHKIoD).

Vitoria Owyoung

General Counsel & Company Secretary

Vitoria Owyong is the General Counsel and Company Secretary of the group.

Vitoria oversees the core legal and compliance functions of the company to ensure adherence to relevant legal regulations. She also works with key stakeholders of the company to ensure proper reporting to investors and plays an integral role in the company’s strategic corporate actions and fundraising processes.

Prior to MiRXES, Vitoria was a corporate lawyer at Colin Ng & Partners LLP and CHP Law LLC with legal experience in mergers and acquisitions, private equity, corporate governance, restructuring and fundraising. Vitoria played vital roles in the expansion of her clients’ companies across the APAC region by advising on legal matters and facilitating fundraising projects. During her time in legal advisory, Vitoria worked closely with companies across different growth stages and takes a particular interest in early-stage companies where she feels most fulfilment taking companies through to the next phase of growth.

Vitoria graduated from the Australian National University. She was admitted to the bar at the Supreme Court of Australian Capital Territory. She is entitled to engage in legal practice as Barrister and Solicitor and was a registered foreign lawyer in Singapore.